title: The birth of ocular pharmacology in the 20th century.
abstract: Nineteenth century ophthalmology, characterized by significant gains in diagnostic techniques, provided the basis for great advancements in treatment during the 20th century. Drug therapy at the turn of the century was empiric, palliative, and often toxic. The development of ocular pharmacology during the 20th century provided the basis for a rational therapeutic approach to ocular disease. Foremost among the therapeutic developments were antibiotics, due to their potential to cure conditions that frequently resulted in blindness. Second, other therapeutic classes provided palliative therapy for chronic diseases, and thus decreased morbidity. For example, drugs specifically targeting many different aspects of glaucoma have had remarkable success controlling intraocular pressure and forestalling development of blindness. In addition, other new approaches provided palliative therapy for nonblinding conditions and effective adjuncts to surgical procedures. Antiallergy and anti-inflammatory drugs greatly increased patient comfort and facilitated treatment of allergic and inflammatory reactions. Local anesthetics and analgesia reduced patient discomfort during surgery. Other adjunct drugs improved surgical outcomes by reducing inflammation and infectious complications. The 21st century will undoubtedly provide novel approaches to address many of today's therapeutic dilemmas. Photodynamic therapy, growth factors, antisense technology, and genetic-based therapies all show great promise. Many of the conditions that are only treated palliatively today will be curable in the next century using many of these pharmacological advances.
authors.affiliation: Thomas R. Lee Center for Ocular Pharmacology, Eastern Virginia Medical School, Norfolk 23501, USA.
authors.forename: P B
authors.initials: PB
authors.lastname: Williams
authors.forename: E R
authors.initials: ER
authors.lastname: Crouch
authors.forename: J D
authors.initials: JD
authors.lastname: Sheppard
authors.forename: F A
authors.initials: FA
authors.lastname: Lattanzio
authors.forename: T A
authors.initials: TA
authors.lastname: Parker
authors.forename: P V
authors.initials: PV
authors.lastname: Mitrev
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001766:Blindness / Q000209:etiology / Q000517:prevention & control; D005128:Eye Diseases / Q000150:complications / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D005901:Glaucoma / Q000209:etiology / Q000601:surgery; D049673:History, 20th Century; D006801:Humans; D009184:Mydriatics / Q000008:administration & dosage / Q000627:therapeutic use; D009885:Ophthalmology / Q000266:history* / Q000639:trends; D010166:Palliative Care
chemical_list: D018926:Anti-Allergic Agents; D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D009184:Mydriatics